Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Manual of Policy and Procedures describes specific actions FDA review staff will take once a product has received “breakthrough therapy” designation, with an emphasis on more meetings, more frequently.


Related Content

Surge In Applications Triggers User Fee Inflation
Breakthrough Designation Is A Two-Way Street, FDA Cautions Sponsors
REMS, ‘Breakthrough’ Meetings Get ‘Type B’ Tag In Revised FDA Guidance
Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell
Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell
The Atypical Commissioner Turns Out Well: Hamburg Receives Mostly Fond Farewell
Would Pulling A "Breakthrough" Break The Program?
Zykadia Expedited Timeline Challenged By Late-Breaking GMP Concern
Sovaldi NDA Review Marred By Manufacturing Compliance Issues
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts